What are the most valuable medical imaging AI startups?

Top startups in the medical imaging AI market ranked by valuation

Here is the current ranking of the most valuable medical imaging AI startups. For each one you will also find our confidence level and the valuation basis we used.

If you want to go deeper into the medical imaging AI startup landscape, check our report covering the medical imaging AI market.

1. PathAI: $750M is the announced upfront price from Roche; closing unconfirmed.
2. Total funding is a minimum: some rounds have no public amount.
3. Total funding includes the primary proceeds of its IPO.

Is Aidoc really the most valuable medical imaging AI startup?

Aidoc is the most valuable medical imaging AI startup in our ranking, although its lead over Viz.ai rests on an estimate rather than an announced price.

We place Aidoc first at $1.0B–$1.9B and count $436M in equity raised. Its last recorded financing is the $150M round of April 2026. The range is our estimate from the size of that round, not a price announced by Aidoc or its investors, which is why its confidence is low. We order companies by the middle of each range taken in proportion, and that puts Aidoc just above Viz.ai's announced $1.2B. Because that figure sits inside Aidoc's range, the gap between the two is much smaller than their rank numbers suggest.

Aidoc started with algorithms that flag urgent findings in medical scans. It now also connects clinical teams and helps hospitals run AI from other suppliers. In April 2026, Aidoc announced financing led by Goldman Sachs to develop its clinical foundation model and expand the platform. In August, it described a group of US health systems working together on diagnostic AI implementation.

The opportunity is a much bigger hospital software contract than one scan-reading tool could win alone. Aidoc still has to show that hospitals will keep paying for that wider role. It has earned its place at the top of our ranking, but only a new priced round would show how far ahead it really is.

What happened to Shukun Technology's medical imaging AI valuation?

Shukun Technology no longer has a current valuation in our medical imaging AI ranking, because its last published price is more than five years old.

The Chinese company was reported at $1.45B in 2021, and we count $181M in equity raised. Its last recorded funding, a strategic round in February 2022, disclosed neither an amount nor a price. That 2021 price is now more than five years old, and no priced round has followed, so we list Shukun at the end of our table without a rank and do not count it as a unicorn.

Shukun has kept working on its products since that financing. It sells AI for coronary CT scans and other diagnostic images. The company announced an FDA clearance for coronary CTA analysis in September 2025, alongside progress with regulators in Europe and Japan. Those clearances give it a route into more hospitals, where medical software has to pass clinical and regulatory checks before doctors can use it.

Still, a product approval does not tell us what new investors would pay today. Shukun may be worth more or less than its old price, and without a recent priced round we cannot place it in the ranking. A new financing with a disclosed valuation would bring it straight back into the comparison.

Is Viz.ai still a billion-dollar medical imaging AI company?

Viz.ai is still a medical imaging AI unicorn on its last announced private valuation, although that price is several years old.

Viz.ai announced a $1.2B valuation with its April 2022 Series D+, which ranks it second. We record $171M+ in equity funding, with the plus sign marking a minimum. Its original stroke software identified urgent scan findings. The company then built tools to alert specialists and coordinate treatment, so the image result starts a care process instead of simply producing another report.

In January 2025, Viz.ai said its platform had reached 1,700 hospitals and healthcare systems and 60,000 American healthcare providers. It also announced partnerships with large pharmaceutical companies. Those are meaningful signs that clinicians use its platform beyond a small pilot program.

What they cannot prove is a fresh equity price. Hospital adoption makes Viz.ai more convincing than a company living on a fundraising announcement alone, but its market value has not been reset publicly by those deployment figures. We still count Viz.ai as a unicorn, with the age of that valuation made clear.

Are there actually many medical imaging AI unicorns?

Medical imaging AI has only 2 startups whose full valuation figure or range reaches the $1B unicorn threshold.

That is 1% of the 146 startups we track. The other 143, or 99%, are in the sub-billion-dollar bracket, and Shukun Technology has no current valuation. The two names that clear the line are Aidoc and Viz.ai. The estimates for Cleerly and DentalMonitoring reach above the threshold at their high ends, but their low ends stay below it.

The two unicorns both work inside hospital workflows. Aidoc runs clinical detection and workflow tools, while Viz.ai connects imaging alerts to care teams. The two companies closest to the line come from other specialties, with Cleerly in coronary plaque analysis and DentalMonitoring in orthodontic monitoring.

This count also keeps public stock prices and acquisition values separate. HeartFlow is a useful comparison, but public investors set its price every trading day. That is quite different from what a startup was worth when it last raised private money.

Is DentalMonitoring really worth unicorn money for analyzing teeth?

DentalMonitoring is close to unicorn value in medical imaging AI, and it has a real orthodontic business behind its estimate.

We estimate DentalMonitoring at $667M–$1.2B from the size of its February 2026 Growth Equity round, which ranks it fourth, and count $300M in equity raised. It was reported at $1.0B in 2021, but that price is now more than five years old, so the newer round sets our range. Because the low end is under $1B, we do not count it as a unicorn. Patients take images of their teeth during treatment, and the software helps orthodontists follow changes between appointments. That gives practices a reason to use it throughout a course of care rather than only when a patient comes in for a scan.

There is evidence beyond the fundraising headline. In February 2026, investor Lazard Elaia Capital said DentalMonitoring had reached operational profitability in 2025. The new investment was intended to support international growth and further AI development. Profitability is a stronger proof point than a promise that doctors might eventually adopt an app.

DentalMonitoring also shows why medical imaging AI cannot be limited to hospital radiology. The images are taken by patients, but a clinician uses the analysis to monitor treatment. For this business, repeat use inside orthodontic practices matters more than trying to do every kind of medical scan.

Who is winning medical imaging AI, China or the United States?

The United States is ahead of China in medical imaging AI, with more companies and higher-ranked ones, while Israel's Aidoc holds first place.

China's highest-ranked startup is Deepwise, in sixth place, estimated at $463M–$869M from the size of its January 2025 round. Shukun Technology, whose last published price dates from 2021, has no valuation under five years old. We count 42 US startups and 6 Chinese ones, and the United States holds three of the top five places with Viz.ai, Cleerly and PathAI. Adding estimates and old financing prices together would give a misleading country league table, so we compare ranks and counts instead.

The US group includes Viz.ai in stroke care, Cleerly in coronary plaque analysis, Overjet in dentistry and ArteraAI in cancer pathology. Other countries bring their own contenders. Israel has Aidoc, France has DentalMonitoring, the United Kingdom has Ultromics, and Australia's Harrison.ai sells radiology and pathology software. In February 2025, Harrison.ai said it was expanding in the United States. AIRS Medical has similarly been working to make its MRI software useful across scanner brands.

The answer depends on what we call winning. The United States has the deeper field and more of the top places, Israel has the leader, and companies from several countries are selling into overseas hospitals. None of that yet tells us which country will earn the most from medical imaging AI.

The table below shows the highest-ranked medical imaging AI startup from each selected country.

Startup	Country	Valuation
Aidoc	Israel	$1.0B–$1.9B
Viz.ai	United States	$1.2B
DentalMonitoring	France	$667M–$1.2B
Deepwise	China	$463M–$869M
Harrison.ai	Australia	~$521M
Ultromics	United Kingdom	$367M–$688M
Qure.ai	India	$350M–$700M
Quibim	Spain	$250M–$417M
AIRS Medical	South Korea	$148M–$278M

Why isn't HeartFlow the most valuable medical imaging AI startup?

HeartFlow still counts as a medical imaging AI startup, since it listed only in 2025, but its stock-market value is shown apart from the private valuations.

We show HeartFlow separately at a $5.1B public market capitalization. Its software analyzes coronary CT scans to help doctors assess blood flow and plaque. That puts its clinical work close to Shukun Technology, Cleerly and Elucid. But a public share price moves with the stock market, while the private valuations in our main comparison come from rounds, reports or estimates.

HeartFlow also gives investors more information about the business itself. In its latest quarterly release, the company reported third-quarter revenue of $72.9 million. By the end of September, its platform had been used to assess coronary artery disease in more than 800,000 patients. Public financial reports let readers test that activity against spending and losses, which is harder to do for private startups.

HeartFlow is therefore a useful benchmark for how valuable coronary imaging software can become. Calling it the leading private startup, though, would mix two kinds of company and two different ways of setting a price.

Did Roche's PathAI deal create another medical imaging AI unicorn?

Roche's PathAI deal did not create another medical imaging AI unicorn because its recorded acquisition value sits below the threshold.

We record PathAI at a $750M acquisition value. Roche announced the agreement in May 2026, explaining how PathAI's software could fit with its diagnostics business. The figure describes a deal between companies, not a fresh equity round that priced PathAI as an independent startup.

PathAI analyzes digital tissue slides and works on pathology images and biomarkers. Roche already sells diagnostic equipment and tests to laboratories. Putting PathAI software into those relationships could make it easier to sell, particularly when a pathology result helps determine which drug a patient should receive. Roche's more recent digital pathology materials describe how the offerings fit together.

The purchase shows that large diagnostics companies want pathology AI they can distribute. It does not tell us what an independent investor would have paid for PathAI without Roche's sales channels. That is why we keep the acquisition label attached to this valuation.

Could Cleerly become the next medical imaging AI unicorn?

Cleerly could join the medical imaging AI unicorn group, but its valuation has not been confirmed above $1B.

We estimate Cleerly at $700M–$1.3B using comparable companies, and count $372M in equity raised. Its last recorded financing was a December 2024 Series C. The range is our estimate, not a valuation disclosed by Cleerly or its investors. The middle of that range, taken in proportion, places Cleerly third, ahead of DentalMonitoring's estimate and PathAI's $750M acquisition value. Since part of it falls below the unicorn line, we do not count Cleerly as one yet.

Cleerly uses coronary CT scans to measure plaque and help doctors understand heart disease. The company said its December 2024 financing extension would support commercial expansion and clinical research. Shukun Technology also works on cardiovascular imaging, while public company HeartFlow offers another way to assess coronary disease. They address related clinical problems, but they have different products and routes to hospitals.

Cleerly's biggest opportunity is to make plaque measurement a routine part of heart care. That depends on doctors using the result, patients benefiting and payers supporting the service. A valuation range that touches unicorn territory is promising, but a repeatable business and a new priced round would give us a firmer answer.

Is Indian medical imaging AI startup Qure.ai undervalued?

Qure.ai could be undervalued, but the available medical imaging AI valuations cannot prove it is a bargain.

We estimate Qure.ai at $350M–$700M from comparable companies. Its last recorded financing was a September 2024 Series D+, and its products analyze X-rays and CT scans. Aidoc and Viz.ai have higher positions, but they also sell tools that connect the scan finding to teams and treatment. The companies are not charging hospitals for exactly the same service.

Qure.ai's regulatory materials describe FDA-cleared tools for lung nodules on chest X-rays and for emergency brain CT analysis. That gives clinicians concrete tasks to assess. Hospitals can compare accuracy, turnaround time, workflow fit and the number of cases that need the software. A hospital-wide platform may win a larger contract, yet a specialist model can be valuable when it solves a hard clinical problem reliably.

Without comparable sales, contract renewals and margins, calling Qure.ai cheap would be a guess. We see a serious international medical imaging AI competitor whose estimated price is below several better-known US platforms. The difference alone is not evidence of mispricing.

Can Overjet, Pearl and Videa catch DentalMonitoring in dental AI?

Overjet, Pearl and Videa could narrow the dental AI valuation gap, but DentalMonitoring still leads with a higher estimated range.

We record Overjet at $550M and Pearl at $400M, both reported with private rounds. Videa is at $267M–$500M, which is our estimate based on the size of its January 2025 Series B and dated to that round, not a price its investors announced. DentalMonitoring's range is an estimate from its February 2026 round, and Overjet's $550M sits just below its low end. DentalMonitoring follows orthodontic patients between visits. These three competitors focus more on reading dental X-rays and helping dentists make decisions during appointments.

Overjet is already working with large practice groups. In June 2026, it said Dental Care Alliance was introducing its products across more than 400 affiliated practices, covering imaging as well as voice and claims tasks. Pearl also offers chairside AI-assisted diagnosis, while Videa brings image interpretation into the normal dental workflow. Those products can become part of more than a single X-ray review.

The contest is now about how often practices use and pay for the software. DentalMonitoring can sell through an entire treatment program, while X-ray providers can grow through diagnosis, patient communication and operations. That gives the challengers room to build much bigger businesses, even if their last valuation evidence does not yet match the leader.

Can heart-scan AI startups beat general radiology AI platforms?

Heart-scan AI has produced some of the most valuable medical imaging startups, but broad radiology platforms remain serious rivals.

Shukun Technology sells cardiovascular scan analysis. Cleerly and Elucid focus on plaque seen in coronary CT, while Ultromics finds disease signals in cardiac ultrasound. We place Elucid and Ultromics at $367M–$688M each, a tie at the displayed figures. All of them try to help doctors make treatment decisions with information from images.

Ultromics has described EchoGo as a way to find cardiac problems that are easy to miss in routine ultrasound. In 2025, the company said its technology had processed more than 400,000 cases. HeartFlow's public company reports offer another example of a cardiovascular software company reaching real patients, although we keep its market capitalization out of the private ranking.

The broader platforms work differently. Aidoc can flag multiple conditions, Viz.ai follows patients into treatment workflows, and Sirona Medical aims to organize radiologists' everyday work. Heart-scan specialists may charge for a high-value diagnostic decision. General platforms have a chance to be used across more departments. Both routes are attracting meaningful valuations, and neither has settled the race.

Can digital pathology AI startups rival radiology AI valuations?

Digital pathology AI startups are attracting major valuations and buyers, although radiology companies still hold the highest private positions.

PathAI's deal with Roche is one example. We estimate ArteraAI at $360M–$900M from the size of its February 2024 round, and Ibex Medical Analytics at $180M–$380M and Aignostics at $145M–$250M from comparable companies. None of these is a price announced by investors. ArteraAI's range is wide, and its middle, taken in proportion, places it seventh, just ahead of Overjet's reported $550M. The products work with tissue images to find cancer patterns, estimate outcomes or help researchers identify patients for clinical studies.

ArteraAI says its prostate cancer test appears in National Comprehensive Cancer Network guidance, which could help clinicians use image-based predictions when planning treatment. Roche has discussed pathology biomarkers and diagnostic testing alongside PathAI's software. In both cases, the result can influence a medical decision that goes well beyond marking a suspicious area on a slide.

Radiology platforms still hold the top private valuation positions, from Aidoc and Viz.ai to Deepwise. Pathology is building a meaningful business of its own, especially where image results guide cancer treatment. One acquisition and a collection of estimated prices do not yet put it ahead of radiology overall.

Can MRI AI startups succeed without diagnosing disease?

MRI AI startups can be valuable by making scans faster and clearer, even when they do not diagnose a disease.

Subtle Medical is estimated at $220M–$412M, Vista AI at $197M–$369M and AIRS Medical at $148M–$278M, each from the size of its last round rather than a published price. Their tools improve image acquisition, reconstruction or scan quality. A hospital may buy those products to use its existing scanner more efficiently, regardless of whether it adds another disease-detection algorithm.

In September 2026, AIRS Medical described a broader set of MRI software products designed to work across scanner brands. Subtle Medical announced FDA clearances for PET and CT image enhancement in May and June 2026, expanding beyond its MRI work. Both companies are trying to become useful in more parts of a hospital's imaging department instead of depending on one narrow product.

The payoff is practical: more usable images from the equipment a hospital already owns. The software still has to meet clinical quality standards and work reliably on different machines. That is a different path to a high valuation from replacing a radiologist's interpretation, but it can be a good business.

Can hospital-wide medical imaging AI beat single-purpose tools?

Hospital-wide medical imaging AI platforms could become more valuable than single-purpose scan readers because hospitals use them across more workflows.

Aidoc combines detection, triage and AI deployment. Viz.ai moves from scan findings into treatment coordination. Sirona Medical, estimated at $267M–$500M from its October 2026 round, sells a radiology workspace. Rad AI, which builds radiology reporting software, announced a $525M valuation with its January 2025 Series C, which places it 9th. Incepto Medical, which helps hospitals deploy imaging AI applications, is estimated at $107M–$200M. Each tries to become part of the system clinicians work in every day.

Sirona's materials describe Cortex as a way to connect radiology worklists, scan context and specialized algorithms. Aidoc has also talked about running models from other vendors. Those tools can spare hospitals the work of buying and managing every AI product separately. But the broader software still has to save clinicians time, and another dashboard alone will not justify a larger contract.

A specialist can still win when its result is hard to reproduce and doctors use it often. Platform companies, meanwhile, can grow if hospitals choose them to connect multiple tools. The valuations point to real interest in both models, with an advantage for whichever software becomes routine in clinical work.

Can South Korean medical imaging AI startups catch the leaders?

South Korean medical imaging AI startups have credible products, but their private valuations are still below the global leaders.

We track 8 South Korean startups. AIRS Medical focuses on faster MRI scans, Hutom on surgical planning, Promedius on age-related disease imaging and Mediwhale on cardiovascular risks seen in retinal images. We estimate Hutom at $156M–$234M, Promedius at $106M–$199M and Mediwhale at $87M–$164M.

AIRS Medical's September 2026 product announcement showed a clear direction: sell software that works across more scanners and hospital workflows. That could expand its market beyond an imaging department using one MRI enhancement tool. Korean startups are also working on retinal screening and surgery, so their business prospects do not depend on a single radiology product.

To reach the top valuation group, these companies will need more international customers and repeatable sales. South Korea already has a solid range of specialists, though there is no evidence in these valuations that it has displaced the biggest Chinese, Israeli or American companies.

Can European medical imaging AI startups catch the global leaders?

European medical imaging AI startups are competitive in several specialties, but the global valuation lead still sits elsewhere.

We count 19 French startups and 17 from the United Kingdom. DentalMonitoring is Europe's highest-ranked name, and the British group includes Ultromics, Brainomix and Perspectum. Spain has Quibim in imaging biomarkers, while Germany has Aignostics in pathology and deepc in radiology AI deployment. Europe's companies are spread across several important jobs rather than one dominant product type.

Some are already finding customers or partners outside their home markets. DentalMonitoring's investors emphasized international expansion in February 2026. Brainomix described an extension of its work with Boehringer Ingelheim in May 2026, using AI measurements from lung scans in pulmonary fibrosis research. Orthodontics and lung research have little in common commercially, but both show routes to an international market.

Europe's best chance is to turn these specialized products into businesses that can sell repeatedly across countries. It has plenty of candidates, and DentalMonitoring's estimate reaches unicorn level at its high end. For now, however, Israel and the United States occupy the top private valuation positions.

Does FDA clearance make a medical imaging AI startup valuable?

FDA clearance helps a medical imaging AI startup sell clinical software, but it does not guarantee a high valuation.

Shukun Technology, Aidoc, AIRS Medical and Subtle Medical have pursued regulatory authorization for their products. The FDA's list includes radiology, dental and other AI-enabled medical devices. Each authorization concerns a particular medical use. It cannot tell us whether the product will fit a hospital's workflow or attract enough paying customers.

Consider Subtle Medical, which enhances medical images, and Aidoc, which detects conditions and helps manage cases. Both deal with regulated clinical software, but hospitals buy them for different reasons. ScreenPoint Medical, estimated at $120M–$220M, has taken another route to proving usefulness: its Transpara breast imaging AI has been studied in randomized mammography screening trials, including Sweden's MASAI study.

Clearance opens doors. Clinical studies, integration and routine use decide how far the business can go after that. A company can have authorized software and still struggle to sell it, while a tool that saves time or improves care may earn a much larger place in the hospital budget.

Are today's medical imaging AI valuations still tied to old deals?

Some well-known medical imaging AI valuations still come from old rounds, even though the businesses have changed since then.

Viz.ai's $1.2B dates to its April 2022 round. Shukun Technology shows how far this can go. Its last published price, set in 2021, is more than five years old, and the round it raised after that disclosed no price, so we no longer show a valuation for it. DentalMonitoring was also reported at $1.0B in 2021, and we now estimate it from its February 2026 round instead. New products and more customers may have changed what investors would offer today, but they do not create an automatically updated valuation. A newer financing also does not always disclose a new price.

Aidoc shows the opposite problem. Its $1.0B–$1.9B figure is our estimate from the size of its April 2026 round, dated to that round. PathAI's $750M, by contrast, is the value of Roche's acquisition. We rank Aidoc ahead of PathAI using the middle of its range taken in proportion, but the two figures have different levels of certainty.

When we compare the leaders, we put more weight on whether an amount was actually reported, implied by a deal or estimated from other evidence. That distinction keeps a historical headline from looking like a live quote, and it helps explain why an estimated company can appear above one with a stated value.

Do the biggest medical imaging AI valuations reflect real businesses?

Several top medical imaging AI startups have real clinical customers and products, but a big valuation still tells us little about profits.

DentalMonitoring's investor has reported operational profitability. Viz.ai has described a large hospital network, and Aidoc works with health systems on diagnostic AI. Those are encouraging facts, though they measure different things. A business can have a widely used product and still spend heavily to grow it.

The market also has a substantial group of specialist companies well below unicorn territory. Clairity's breast cancer risk software has a $137M valuation reported with its last round, Mediwhale's retinal imaging software sits at $87M–$164M, and Brainomix's stroke and lung tools are estimated at $43M–$81M. Their work may matter to clinicians even without the highest valuation. ScreenPoint Medical's mammography trials similarly test whether a specific product helps screening teams.

HeartFlow's public filings give a much clearer financial view than most private startups provide. Among companies eligible for our valuation-to-equity-funding comparison, Pearl has the highest multiple at 5.8x, while the lowest is Overjet at 3.5x. Those are not revenue multiples, and neither proves that a company earns money. To judge whether a valuation is deserved, we would need comparable revenue, margins and cash flow alongside clinical use.

So, which medical imaging AI startups are worth the most today?

Aidoc is the most valuable medical imaging AI startup in our ranking, with Viz.ai close behind as the only other company in the billion-dollar group.

Aidoc's position rests on an estimate from its April 2026 round, and Viz.ai's announced price sits inside that range, so we would not treat the rank order as a huge gap in what investors might pay. Viz.ai remains a unicorn on its last announced private round. Shukun Technology drops out of the ranking because its last published price, from 2021, is more than five years old.

Below them, Cleerly and DentalMonitoring have estimates that reach past $1B at the high end, Deepwise is China's strongest name, and PathAI's deal with Roche shows why large diagnostics companies care about image AI. Cardiovascular analysis, radiology coordination, pathology, dentistry and scanner enhancement can all support valuable companies. They simply reach customers in different ways.

Our main judgment is that Aidoc leads, but no startup has put the rest of the field out of reach. Public market values, acquisition deals, reported private prices and estimates tell different stories. The next shift in the rankings will depend on actual customer use and newly priced transactions, rather than the loudest clinical AI announcement.

The table below shows what we found.

Question	Answer
Is the valuation leader comfortably ahead today?	No, Aidoc leads, but the medical imaging AI race stays close. Viz.ai's announced $1.2B sits inside Aidoc's $1.0B–$1.9B range. Overlapping figures leave room for a change in leadership.
Have medical imaging AI unicorns become common?	No, the billion-dollar group remains a small minority of startups. Only 2 companies clear the line across their full valuations. That leaves many promising companies below the famous threshold.
Does the United States own the top spot?	No, Israel's Aidoc holds first place in our ranking. We count 42 US startups in this market. American breadth gives it second and third place with Viz.ai and Cleerly.
Has Europe produced a serious imaging AI contender?	Yes, Europe has built valuable companies across several specialties. France alone contributes 19 startups to the group we track. DentalMonitoring's estimate reaches unicorn level at its high end.
Can investors pin Aidoc to one valuation?	No, Aidoc's last round only supports a valuation range. Our figure for Aidoc is $1.0B–$1.9B. Viz.ai's announced price falls inside that range.
Does Viz.ai still have real clinical reach?	Yes, Viz.ai has a large hospital and provider network. The company reported reaching 1,700 hospitals and healthcare systems. Hospital adoption supports its business, though it cannot reset equity prices.
Can dental AI support a unicorn business?	Possibly, orthodontic monitoring is close to the billion-dollar line. We estimate DentalMonitoring at $667M–$1.2B from its February 2026 round. Dental X-ray competitors still have ground to make up.
Did pathology AI produce a big exit?	Yes, Roche's PathAI deal puts a substantial price on pathology software. PathAI carries a recorded acquisition value of $750M. An acquisition measures something different from an independent private round.
Can MRI software win without diagnosing patients?	Yes, speeding up scanners can support a valuable software company. Subtle Medical is estimated at $220M–$412M from its last round. Hospitals may pay to get more from equipment they own.
Is FDA clearance enough to justify valuations?	No, approval helps products reach doctors but cannot guarantee sales. ScreenPoint Medical has an estimated valuation of $120M–$220M. Its clinical trials matter alongside any regulatory authorization.
Do high valuations prove strong company finances?	No, a high private valuation cannot establish financial health alone. We cover 146 medical imaging AI startups with very different businesses. Revenue, repeat customers and cash flow would settle that argument.